Sonnet Biotherapeutics Holdings Inc (SONN)
$5.62
Live
Performance
- $5.60$6.26$5.62
0.36%
Downside
Day's Volatility :10.48%
Upside
10.16%
- $4.37$19.68$5.62
22.24%
Downside
52 Weeks Volatility :77.79%
Upside
71.44%
Returns
| Period | Sonnet Biotherapeutics Holdings Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -14.0% | 0.0% |
6 Months | -56.42% | 0.0% |
1 Year | -63.34% | 0.0% |
3 Years | -99.64% | -23.0% |
Highlights
Market Capitalization | 4.0M |
Book Value | $4.01 |
Earnings Per Share (EPS) | -0.96 |
Wall Street Target Price | 148.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -21968.55% |
Return On Assets TTM | -96.93% |
Return On Equity TTM | -264.57% |
Revenue TTM | 55.9K |
Revenue Per Share TTM | 0.12 |
Quarterly Revenue Growth YOY | -50.0% |
Gross Profit TTM | -21.1M |
EBITDA | -12.3M |
Diluted Eps TTM | -0.96 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -12.84 |
EPS Estimate Next Year | -14.96 |
EPS Estimate Current Quarter | -0.76 |
EPS Estimate Next Quarter | -0.63 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 2533.45%
Technicals Summary
Sell
Neutral
Buy
Sonnet Biotherapeutics Holdings Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Sonnet Biotherapeutics Holdings Inc | -21.73% | -56.42% | -63.34% | -99.64% | -99.96% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Sonnet Biotherapeutics Holdings Inc | 0.25 | NA | NA | -12.84 | -2.65 | -0.97 | NA | 4.01 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Sonnet Biotherapeutics Holdings Inc | Buy | $4.0M | -99.96% | 0.25 | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Sonnet Biotherapeutics Holdings Inc
Decreasing Revenue
Revenue is down for the last 2 quarters, 37.25K → 18.62K (in $), with an average decrease of 50.0% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 365.42K → -3.50M (in $), with an average decrease of 1059.3% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 151.7%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 144.4%
Institutional Holdings
Armistice Capital, LLC
5.23%Sabby Management LLC
4.58%Virtu Financial LLC
0.63%Geode Capital Management, LLC
0.32%Vanguard Group Inc
0.28%Tower Research Capital LLC
0.14%
Company Information
sonnet biotherapeutics is an early stage company developing a pipeline of bifunctional therapies that attack immune-modulating targets to control cancer cells. sonnet biotherapeutics is utilizing a platform approach to develop a library of cancer-fighting immunotherapies. sonnet is based in cranbury, new jersey. sonnet mission: sonnet biotherapeutics is a platform enabled proof-of-concept engine created to generate immuno-oncology candidates and develop them into phase ii assets. we are leveraging a unique ip driven platform: ● single chain platform with pk enhancement ● selectively targeting tumors and their micro-environment ● validated targets only ● dual targeting can create synergies
Organization | Sonnet Biotherapeutics Holdings Inc |
Employees | 12 |
CEO | Dr. Pankaj Mohan Ph.D. |
Industry | Consumer Services |
Discover More
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$5.62
-4.91%
Invesco Bulletshares 2025 Hi
$5.62
-4.91%
Schwab International Dividend Equity Etf
$5.62
-4.91%
Blockchain Coinvestors Acquisition Corp.
$5.62
-4.91%
Allgiant Travel Company
$5.62
-4.91%
Rogers Corp
$5.62
-4.91%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$5.62
-4.91%
Iheartmedia
$5.62
-4.91%
Lightpath Technologies Inc
$5.62
-4.91%